- In May 2024, Sherlock Biosciences initiated clinical trials for an over-the-counter rapid molecular test designed to detect sexually transmitted infections (STIs) such as chlamydia and gonorrhea. This innovative CRISPR-based test aims to deliver results within 30 minutes, enhancing accessibility and privacy for users. The company plans to launch the test by mid-2025, marking a significant advancement in at-home STI diagnostics
- In 2024, the Biomedical Advanced Research and Development Authority (BARDA) partnered with Sherlock Biosciences to develop a home-use molecular test capable of detecting and differentiating SARS-CoV-2, influenza A, and influenza B viruses. Utilizing isothermal amplification technology, this test represents a step forward in multiplexed at-home diagnostics for respiratory illnesses
- In 2024, the U.S. Food and Drug Administration (FDA) issued an Emergency Use Authorization (EUA) for certain RT-PCR molecular-based tests developed by laboratories for the detection of SARS-CoV-2. These tests are designed for use as part of a serial testing program, enhancing the availability of at-home molecular diagnostics during the COVID-19 pandemic
